LEXINGTON, Mass.–(BUSINESS WIRE)–Jun. 27, 2018– Translate Bio, Inc. (Nasdaq: TBIO) a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of its initial public offering of 9,350,000 shares of its common stock at a price to the public of $13.00 per share, for total gross proceeds of approximately $121.6 million, before deducting underwriting discounts and commissions and expenses payable by Translate Bio. In addition, Translate Bio has granted the underwriters a 30-day option to purchase up to 1,402,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares are being offered by Translate Bio. The shares are expected to begin trading on the Nasdaq Global Select Market on June 28, 2018 under the symbol “TBIO.” The offering is expected to close on July 2, 2018, subject to customary closing conditions.
This press release features multimedia. View the full release here.